Form 4: Day One Biopharmaceuticals Director Garland J. Scott Granted New Equity Awards

Day One Biopharmaceuticals, Inc. Director Garland J. Scott received new equity compensation, including stock options and restricted stock units, as disclosed in a recent SEC Form 4 filing.

Summary

• Director Garland J. Scott of Day One Biopharmaceuticals, Inc. (DAWN) was granted new equity awards on June 2, 2025.
• The awards include 22,500 stock options with an exercise price of $7.01 per share.
• These stock options will vest at a rate of 1/12th of the total grant on each monthly anniversary, beginning July 2, 2025, contingent on continued service.
• Additionally, 15,000 Deferred Restricted Stock Units (RSUs) were granted.
• Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.
• The RSUs will vest 100% on the earlier of June 2, 2026, or the date of the Issuer's 2026 annual meeting of stockholders, subject to continued service.
• Upon vesting, the RSUs will automatically convert into an equal number of deferred stock units, which will be settled for shares by calendar year 2030 or upon the Reporting Person's separation from the Issuer.

Sentiment

Score: 7

Explanation: The filing discloses routine equity compensation for a director, which is a positive mechanism for aligning interests and encouraging long-term commitment, with no negative financial implications or operational issues disclosed.

Positives

• The granting of equity awards to a director aligns the director's financial interests with those of the company's shareholders, encouraging long-term value creation.
• The vesting schedules for both stock options and RSUs incentivize the director's continued service and commitment to the company's success.

Risks

• The vesting of both stock options and restricted stock units is contingent upon the Reporting Person's continued provision of service to the Issuer.
• Deferred stock units may settle earlier than 2030 upon the Reporting Person's death, disability, separation from service, or the occurrence of an 'unforeseeable emergency' as defined by the Issuer's deferred compensation plan.

Future Outlook

The equity awards are structured to incentivize the director's long-term commitment and align their interests with the future performance of Day One Biopharmaceuticals, with vesting schedules extending into 2026 and settlement of deferred units by 2030.

Management Comments

• The vesting of both stock options and restricted stock units is subject to the Reporting Person's continued provision of service to the Issuer on each vesting date.

Industry Context

This filing reflects a standard practice in the biotechnology and pharmaceutical industry where equity compensation is used to attract, retain, and motivate key personnel, including directors, by aligning their financial incentives with the company's long-term success and shareholder value.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The equity grants align the director's financial incentives with shareholder value, potentially leading to decisions that benefit long-term stock performance.
• Employees: While not directly impacting general employees, the compensation structure for directors can reflect the company's overall approach to incentivizing key personnel.

Next Steps

• Continued service by Garland J. Scott to Day One Biopharmaceuticals, Inc. to fulfill vesting conditions.
• Monthly vesting of 22,500 stock options beginning July 2, 2025.
• Vesting of 15,000 RSUs on the earlier of June 2, 2026, or the 2026 annual meeting of stockholders.
• Automatic conversion of vested RSUs into deferred stock units.
• Settlement of deferred stock units for shares of common stock by calendar year 2030 or upon the director's separation from service.

Key Dates

Recommendation

Keywords

Day One Biopharmaceuticals, DAWN, SEC Form 4, Insider Transaction, Equity Award, Stock Option, Restricted Stock Unit, RSU, Director Compensation, Executive Compensation, Corporate Governance